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future research in drug classes other than antidepressants should
be conducted to verify our ﬁndings.
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OBJECTIVES: Because prescribing in routine clinical practice
reﬂects both the physicians’ perception of the efﬁcacy and safety
of a drug and the patient’s characteristics, this study aimed at
comparing the real-life proﬁle of patients prescribed escitalo-
pram, SSRIs or venlafaxine in primary care in order to better
understand drugs-related determinants of prescription.
METHODS: This retrospective study used data from the General
Practitioners Research Database and included adult patients with
an incident prescription (no antidepressant in the previous12-
month) of escitalopram, an SSRI or venlafaxine between January
1, 2003 and June 30, 2005, and an associated diagnosis of
depression. Demographics, disease and treatment characteristics,
and health care resource consumption were assessed in the
12-month before the new prescription and compared across
treatment groups. RESULTS: A total of 6,910 patients were
prescribed escitalopram, 47,853 SSRIs and 2,832 venlafaxine.
Compared with SSRIs-treated patients, escitalopram-treated
patients were younger (p = 0.001), more often diagnosed with
severe depression (p = 0.018), and more often suffering from
associated anxiety (p < 0.001). They also had more hospitalisa-
tions (p = 0.021), referrals (p = 0.020), anxiolytics (p < 0.001)
and hypnotics (p < 0.001) prescriptions at baseline. Compared
with venlafaxine-treated patients, escitalopram-treated patients
were younger (p < 0.001), less often diagnosed with severe
depression (p < 0.001) and concomitant anxiety (p < 0.001), and
had lighter psychiatric history (p = 0.002). However, they were
more often suffering from cardio-respiratory diseases (p = 0.02).
Baseline resource use was sensibly similar between treatment
groups. CONCLUSIONS: Important differences in patients’ pro-
ﬁles were observed between escitalopram, generic SSRIs and
venlafaxine, and correspond to current data on the drugs’ efﬁ-
cacy and safety proﬁle: physicians prescribed escitalopram and
venlafaxine to patients with more severe depression. The subse-
quent choice between escitalopram and venlafaxine was based on
safety proﬁles, escitalopram being perceived as safer and being
prescribed to patients with a heavier somatic background. These
differences have to be adjusted for in further real-life drug effec-
tiveness studies otherwise they can importantly bias the results.
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OBJECTIVES: Awareness of adult ADHD is low. Even though
guidelines have existed in Germany since 2003, diagnosis and
treatment are not standardized and remain difﬁcult in practice,
often complicated by comorbidities. This analysis investigates
prevalent psychiatric comorbidities and the applied pharmaco-
therapy of adult patients with ADHD diagnosed by general prac-
titioners (GPs) or by neurologists/psychiatrics (NPs) in Germany
in 2007. METHODS: A retrospective database analysis of adult
patients aged 19–59 diagnosed with ADHD (ICD-10 code F90)
was performed, using the IMS Disease Analyzer that contains
electronic medical records of representative panels of German
GPs and NPs, capturing drug prescription and diagnoses.
RESULTS: Patients were identiﬁed through the records of NPs
seeing 122,666 patients and GPs seeing 1.16 million patients,
aged 19–59. NPs diagnosed ADHD in 851 adults (annual preva-
lence 0.69%, 60% male), of which 521 had at least one psychi-
atric co-diagnosis (33% mood disorders F30-39, 19% neurotic,
stress-related and somatoform disorders F40-48). In 214 of 493
GPs’ ADHD patients (annual prevalence 0.04%, 61% male), at
least one psychiatric disorder was co-diagnosed (18% F30-39,
19% F40-48). A total of 48.8% of the NPs’ patients (27.2% of
the GPs’) without a psychiatric comorbidity were treated with
Methylphenidate (MPH) and 5.8% (0.4%) with MPH plus at
least one antidepressant prescription. Treatment differed in
patients with psychiatric comorbidities of which 22.1% (14.0%)
received MPH, but 18.6% (9.8%) MPH plus at least one anti-
depressant. NPs treated other 186 (GPs 142) patients without
diagnosed ADHD (F90) with MPH. CONCLUSIONS: Adminis-
trative prevalence of adult ADHD was low compared to data
derived from literature and both prevalence and comorbidity
proﬁle differed in age, gender and specialist. The pharmaco-
therapy of GPs and NPs depended on prevalent comorbidities
but did not show consistency according to guidelines. A further
understanding of adult ADHD and its treatment opportunities is
needed.
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OBJECTIVES: To describe the frequency of physical injuries and
compare the costs of care from a United States (US) payer per-
spective before and after emergent epilepsy care. METHODS:
This retrospective claims database analysis utilized the PHAR-
Metrics database from 90 regional US health plans. Patients
received care between July 1, 2005 and June 30, 2006 in an
ambulance, emergency room, or inpatient hospital with an
Episode Treatment Grouper of epilepsy without surgery. The
index date was the earliest date of emergent epilepsy care with a
study period of 6 months pre and post-index. Eligible patients
had at least one diagnosis for epilepsy (ICD-9-CM 345.xx,
excluding 345.6) were 12–64 years of age, received 145 days
supply of antiepileptic drugs without emergent care for epilepsy
in the pre-index period, and had continuous eligibility for 6
months pre-index and post-index. Injuries coded on the index
date were described according to ICD-9-CM groupings. Total
epilepsy-related, and non-epilepsy-related direct medical costs
paid to the provider were compared before and after index date
using non-parametric tests for paired samples. Injury-related
costs were also described. RESULTS: A total of 9.4% (n = 146)
of the 1213 patients receiving emergent care for a seizure event
experienced a co-occurring injury on the same date. The majority
of injuries were comprised of superﬁcial injuries and contusions
(28%), fractures (21%), open wounds or injury to blood vessels
(19%) intracranial injury (10%), and/or medication toxicity
(10%). Both per patient non-epilepsy-related (mean =
$3997.23US) and epilepsy-related (mean = US$992.30) direct
medical costs of care pre-index were signiﬁcantly different
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(p < 0.001 for both) from post-index (mean = US$4288.80, and
US$2581.77 respectively). CONCLUSIONS: Approximately one
in ten patients receiving care for epilepsy in an emergent setting
presents with co-occurring injuries according medical claims.
The cost of care for possible re-establishment of epilepsy control
and treating co-occurring injuries is signiﬁcant when compared
to the time period prior to seizure.
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OBJECTIVES: The completion of the genome project was
expected to lead to treatments for genetically-linked disorders.
In many cases this has not occurred. Our aim was to investigate
the published research in one such disorder, Huntington’s
disease (HD), in order to assess the current knowledge in this
area. METHODS: A systematic search of Medline was con-
ducted using a search ﬁlter for RCTs alongside keyword search
strings for HD. Identiﬁed citations were ﬁrst- and second-
passed by two reviewers to determine inclusion/exclusion and
reconciled by a third where decisions disagreed. Top-line data
relating to treatment, included patients, and outcome was then
extracted by two reviewers based on the abstract only. Differ-
ences were reconciled by a third reviewer. keyword search
strings for HD. Identiﬁed citations were ﬁrst- and second-
passed by two reviewers to determine inclusion/exclusion and
reconciled by a third where decisions disagreed. Top-line data
relating to treatment, included patients, and outcome was then
extracted by two reviewers based on the abstract only. Differ-
ences were reconciled by a third reviewer. RESULTS: A total of
397 probable RCTs were identiﬁed: 262 were excluded as non-
RCTs and 135 included for extraction. Twenty-seven abstracts
were unavailable, thus the ﬁnal analysis is based on 108
studies. Of these studies, 29 were conducted in Europe, 29 in
USA, 2 in Mexico, 2 in Israel, and one in Australia and
Canada. The remaining studies did not state country of origin.
Across all included studies 67 treatments were investigated,
with between 3 and 537 patients enrolled. Almost all studies
enrolled 30 individuals or less. Fifty-ﬁve studies reported that
the intervention(s) was effective; 41 reported no efﬁcacy (12 did
not report the results). CONCLUSIONS: The majority of
research in HD has been conducted in Western Europe and the
United States. A wide variety of potential treatments have been
investigated, many of which were ineffective for the treatment
of HD. However, most research enrolled few patients and may
thus lack power to detect any treatment effects. To date no
genetically-related treatments have been developed, which is
surprising given the identiﬁcation of the HD gene in 1993.
Further research into a cure for HD is warranted.
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OBJECTIVES: To determine whether epileptic patients with evi-
dence of an epilepsy-related inpatient, emergency department, or
ambulance treatment claim (deﬁned as an event) and matching
epileptic patients with no evidence of an event differ with respect
to anti-epileptic medication drug formulation changes (either
brand to generic switching or switching between “A-rated” for-
mulations). METHODS: A retrospective case control design
analysis was conducted utilizing PharMetrics® claims between
January 2005 and June 2007. Cases were identiﬁed using an
ICD-9 code of 345.xx and had an epileptic event requiring a
subsequent service code for any of the three care settings of
interest. All patients (cases and controls) were between 12 and 64
years of age, had continuous coverage for at least 6 months and
145 days’ supply of medication prior to their index date. Sta-
tistical analyses were conducted using SAS®. RESULTS: There
were 11,360 patients that met inclusion criteria for analysis (991
cases and 10,369 controls). When controlling for age, sex, region
of the country, and type of seizure diagnosis, the odds ratio of the
occurrence of an event between those who switched medication
and those who did not was 1.91 (CI = 1.53 to 2.39). In addition,
a propensity score calculation was conducted to select 991
matched controls for the case group. When performing a logistic
regression using the same variables as above, only switching was
still a signiﬁcant predictor of an event (odds ratio = 1.45;
CI = 1.04 to 1.93) CONCLUSIONS: This analysis found an
association between patients receiving epilepsy care in an emer-
gency department, ambulance, or inpatient setting and the prior
occurrence of formulation switching involving A-rated anti-
epileptic generic medications.
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OBJECTIVES: To compare outcomes of multiple sclerosis (MS)
patients treated with either glatiramer acetate (GA) or inter-
feron beta 1-b (IFN-b-1b) for subcutaneous administration.
METHODS: Data were obtained from i3’s Lab Rx Database
from July 2001 to June 2006. We established an “intent-to-
treat” (ITT) cohort (N = 842) of patients diagnosed with MS
who began therapy on either GA or IFN-b-1b and had con-
tinuous insurance coverage from 6 months before to 24 months
after the date when they began taking the medication. We also
created a “continuous use” (CU) cohort (n = 418) of individu-
als who, in addition to the criteria above, used either GA or
IFN-b-1b within 28 days of the end of the two year post-
period. Using multivariate regressions, we examined both the
two-year total direct medical costs and the likelihood of relapse
associated with the use of each of these MS medications. We
deﬁned relapse as either being hospitalized with a diagnosis of
MS or being diagnosed with MS during an outpatient visit and
then prescribed steroids within a 7-day period. All regression
analyses evaluated a wide range of factors that may affect out-
comes. RESULTS: In the ITT cohort, compared to those who
started therapy with IFN-b-1b, patients who started therapy on
GA had a signiﬁcantly lower two-year risk of relapse (13.54%
v 5.31%; P = 0.0006). In the CU cohort, compared to those
who used IFN-b-1b, patients who used GA also had a signiﬁ-
cantly lower two-year risk of relapse (10.919% v 2.09%;
P = 0.0018) and signiﬁcantly lower total medical costs ($53,185
v $48,130; P = 0.0345). CONCLUSIONS: Results from this
study indicate that, compared to the use of IFN-b-1b, GA use
is associated with signiﬁcantly lower probability of relapse.
Additionally, when comparing continuous users of GA or IFN
beta-1b, there were signiﬁcantly lower two-year total direct
medical costs associated with GA use.
A600 Abstracts
